Fee Pressure, Pharma Tariffs, and a Mega IPO: The iShares MSCI World ETF's Balancing Act at New Highs

URTH hits $202.67 but RSI at 94.6 signals overbought; pharma tariffs, tech concentration, and index changes pose significant risks.

The iShares MSCI World ETF (URTH) closed Thursday at a fresh 52-week high of $202.67, up 0.52% on the day. Yet beneath that milestone lurks a technical red flag: a relative strength index of 94.6, deep in overbought territory. Small shocks could trigger profit-taking, and the calendar over the next few weeks is packed with them — from an index reshuffle and a revamped freefloat methodology to a potential $75 billion SpaceX listing and a fresh wave of US pharmaceutical tariffs.

Pharma tariffs target a sensitive slice of the portfolio

Washington’s planned staggered levy on imported patented drugs, set to begin at the end of July, directly threatens the roughly 10% of URTH’s assets allocated to healthcare. Products from the European Union, Japan, South Korea and Switzerland would face a 15% duty; British goods would be taxed at 10%. Companies without existing US price agreements could be hit with a 100% surcharge.

European and Japanese drugmakers are among the fund’s significant holdings, and FactSet has already trimmed earnings estimates for the sector. Analysts calculate the tariffs could lift inflation by around half a percentage point and squeeze margins. For an ETF that tracks a global index, the impact is real and concentrated.

Tech concentration remains the dominant driver

Despite the healthcare headwind, URTH’s fate is overwhelmingly tied to US technology. Nvidia alone accounts for 5.57% of the portfolio, Apple 4.58%, and Microsoft 3.31% — together more than 13% of assets. American equities overall command over 70% of the fund’s weighting.

That heavy reliance on a handful of mega-cap growth stocks makes the ETF acutely sensitive to interest-rate expectations. The Federal Reserve held its benchmark rate at 3.50%–3.75% at its last meeting, but the 8-to-4 vote was unusually split. With April’s consumer prices rising 0.6% month-on-month (pushing the annual rate to 3.8%), markets now price in no further rate cuts through 2026. A change in the Fed chairmanship adds further uncertainty about future policy tone.

Index changes drive real buying and selling

MSCI published its latest quarterly index review on May 12, with changes taking effect after the close on May 29. The following day, a refined freefloat methodology kicks in on June 1. New additions to the MSCI World index include Medline A, MasTec and TechnipFMC. For a physically replicating ETF, that means tangible portfolio turnover. Because the prior rebalancing was deliberately modest, this one may be more visible.

Meanwhile, the fund continues to attract steady inflows. BlackRock reported net additions of $770 million year-to-date, and Morningstar maintains its Gold rating, citing a 0.02% tracking difference that justifies the 0.24% expense ratio. That fee, however, is looking increasingly stretched: Invesco now charges just 0.05% on its competing MSCI World product, and UBS and BNP Paribas have also cut costs. For large institutional allocators, the gap could start to matter.

Samsung’s surge and the SpaceX wildcard

A bright spot from Asia: Samsung Electronics saw its quarterly operating profit jump eightfold to more than 57 trillion won, pushing its market capitalization above $1 trillion for the first time. That kind of performance helps offset some of the broader index’s reliance on US names.

The biggest potential game-changer, though, remains SpaceX. The space company has confidentially filed for an initial public offering with the SEC, targeting a capital raise of $75 billion at a valuation between $1.75 trillion and $2 trillion. Should it qualify for Nasdaq’s fast-entry rule, index-driven capital could pour in quickly. Inclusion in the MSCI World down the line would further tilt the fund toward software and aerospace, amplifying its US and growth-stock bias.

Dividend date and a near-term outlook

Investors have a concrete date to watch: June 15 is the ex-dividend date for the fund’s semi-annual payout of $1.26 per share. Between now and then, the market will digest the MSCI rebalance (May 29), the freefloat adjustment (June 1), and any new signals on tariffs or monetary policy.

URTH has delivered a total return of 29.14% over the past twelve months and roughly 20% annualized over three years. That run has stretched valuations and left the ETF vulnerable to the unusually dense knot of events converging in the weeks ahead. For a fund built on global diversification, the next fortnight looks anything but diversified in its risks.